The South American MicroBiome Archive (saMBA): enriching the microbiome field by studying neglected populations
- PMID: 40783495
- PMCID: PMC12335589
- DOI: 10.1038/s41467-025-62601-4
The South American MicroBiome Archive (saMBA): enriching the microbiome field by studying neglected populations
Abstract
The human gut microbiome is associated with numerous health outcomes, often in a region-specific manner. Unfortunately, global microbiome research remains profoundly imbalanced: over 70% of sequenced human microbiomes originate from Europe and North America, which together represent only 15% of the world's population. To address this disparity, we developed saMBA-the largest archive of gut microbiomes from South America, one of the world's most microbiome-diverse regions but also among the least studied. The archive comprises 33 studies, ~73% of which had not been included in any previous compendium. A total of 3382 samples were reanalysed, of which 2913 were successfully included after applying quality filters. By leveraging this resource, we reveal both high within-population diversity and between-population uniqueness in the continent, expanding our current understanding of the gut microbiome to be more globally representative. Additionally, saMBA reveals that much of the region's gut microbiome diversity remains undercharacterised, and provides guidance for future sampling efforts to more accurately capture regional biodiversity. The framework used to build saMBA is compatible with existing global resources and is openly available, thus promoting the inclusion of other underrepresented populations to accelerate microbiome research globally.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: J.F.C. has been an invited speaker at conferences organised by Bromotech, Yakult and Nestle and has received research funding from Nutricia, DuPont/IFF, and Nestle. G.C. has received honoraria from Janssen, Probi, Apsen, and Ingelheim Boehringer as an invited speaker; is in receipt of research funding from Pharmavite, Fonterra, Reckitt, Nestle and Tate and Lyle; and has been paid for consultancy work by Yakult, Zentiva, Bayer Healthcare and Heel Pharmaceuticals. This support neither influenced nor constrained the contents of this manuscript. The remaining authors declare no competing interests.
Figures
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
